Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Commercial Officer | June 01, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date June 01, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2031-06-01 | Direct | 400,000 |
Reported balance
After 2021-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-01 · Grant · Acquired 400,000 · Balance 400,000 F1: 25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2021 Filed Jun 8, 2021 17:03 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-038972 · doc4.xml · derivative · entry 1 Priar Robert J · CIK 0001864620 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.